VIR analyst estimates
Vir Biotechnology (VIR) analyst ratings, the average price target and its range, and every firm's latest call.
VIR analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 7, 2026 | H.C. Wainwright | Vir Biotechnology price target raised to $22 from $20 at H.C. Wainwright | $22.00 |
| Aug 6, 2026 | Morgan Stanley | Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley | $25.00 |
| Jun 11, 2026 | Morgan Stanley | Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley | $27.00 |
| May 8, 2026 | Morgan Stanley | Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley | $23.00 |
| Mar 4, 2026 | H.C. Wainwright | Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright | $20.00 |
| Feb 26, 2026 | Leerink Partners | Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners | $20.00 |
| Feb 24, 2026 | Raymond James | Raymond James Upgrades Vir Biotechnology (VIR) to Strong Buy | $19.00 |
| Feb 24, 2026 | Morgan Stanley | Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley | $24.00 |
| Feb 24, 2026 | Needham | Vir Biotechnology (VIR) PT Raised to $18 at Needham | $18.00 |
| Feb 24, 2026 | Evercore ISI | Vir Biotechnology price target raised to $18 from $12 at Evercore ISI | $18.00 |
| Feb 24, 2026 | Barclays | Vir Biotechnology price target raised to $30 from $26 at Barclays | $30.00 |
| Feb 17, 2026 | Barclays | Vir Biotechnology price target raised to $26 from $24 at Barclays | $26.00 |
| Feb 4, 2026 | Barclays | Vir Biotechnology price target lowered to $24 from $31 at Barclays | $24.00 |
| Dec 30, 2025 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR) | $15.00 |
| Jul 11, 2025 | Raymond James | Vir Biotechnology initiated with an Outperform at Raymond James | $12.00 |
- 6 firms rate VIR: 6 buy, 0 hold, 0 sell.
- The average price target is $23.50 from 2 analysts, from $22.00 to $25.00.
Updated 2026-11-03 11:31 UTC